

Safety Pharmacology Solutions

In Vitro Safety Profiling for Early De-Risking


Tiered Off-Target Screening For Every Development Stage

Off-target activity is a leading cause of late-stage drug failure. *In vitro* safety pharmacology profiling evaluates compounds against GPCRs, ion channels, transporters, enzymes, and nuclear receptors clinically linked to adverse drug reactions—enabling discovery teams to design around liabilities before costly *in vivo* studies.

Reaction Biology's InVEST platform provides tiered panels from hit confirmation (InVEST18) through extensive profiling (InVEST77). Functional assays distinguish agonist from antagonist activity. **Kinases profiled at 1mM ATP** reduce false positives. **10 business day turnaround** from Malvern, PA.


Our Solutions for Safety Pharmacology

Determine compound interactions across target classes associated with adverse drug reactions in humans.




In Vitro Safety and Toxicity Screening

- Tiered panels: InVEST18, 44, 59, 77
- Radioligand binding, fluorescence polarization, enzymatic, and functional assays
- GPCRs, ion channels, transporters, kinases, nuclear receptors, and other enzymatic targets
- All kinases at 1mM ATP
- 10 business day turnaround



Cardiac Safety Assessment

- hERG binding (fluorescence polarization)
- Manual patch clamp (MultiClamp 700B): hERG, Nav1.5, Cav1.2, Kv7.1
- Tissue-based action potential recording (Purkinje fibers)
- Langendorff isolated heart (ex vivo whole-heart preparation)



Cytochrome P450 Assays


- 14 CYP isoforms including 1A2, 2C9, 2C19, 2D6, 3A4
- Reversible inhibition screening
- Time-dependent inhibition (TDI) assessment
- CYP induction screening
- High-throughput P450-Glo™ format

Why Choose InVEST?

- **Speed:** 10 business day turnaround for all panel sizes
- **Efficiency:** Monthly screening runs with predictable scheduling
- **Flexibility:** Single-concentration or full dose-response for any target
- **Translational Relevance:** Kinases at 1 mM ATP reduce false positives
- **Quality Assurance:** Reference compound IC₅₀ values included for each assay

Test your compound against our preselected targets or build your own panel suited to your unique project needs


Sample Data: Enzymatic Activity Assay with a PDE




Three reference compounds IBMX, methoxyquinazoline, and Rolipram were tested against the activity of cAMP-specific cyclic phosphodiesterase 4A (PDE4A). Concentration-response curves are shown with semi-log concentrations in singlicates with the following parameters:

- IBMX (blue): IC₅₀= 1.4e-05, hillslope=-0.72
- Methoxyquinazoline (green): IC₅₀= 7.82e-07, hillslope= -0.86
- Rolipram (purple): IC₅₀= 1.1e-06, hillslope= -0.86

Sample data from InVEST Cardiac Recording of hERG current by manual patch



Example recording of hERG current (I_{hERG}) from CHO hERG-Duo cells (B'Sys) using manual patch.



Concentration-dependent effect of E-4031 on hERG current recorded using manual patch (n=23, 6 independent preparations): IC₅₀=294 nM, Hill Slope=-1.53).

Discover our Targets

InVEST Panels


Target Family	Target Name	Assay Format	InVEST18	InVEST44	InVEST59	InVEST77	PDE	CYP	
Bromodomain	BRD4	AlphaScreening Binding			x	x			
COX	COX-1	Enzymatic Activity		x	x	x			
	COX-2	Enzymatic Activity		x	x	x			
Cytochrome P450	CYP1A2	Enzymatic Activity						x	
	CYP2A6	Enzymatic Activity						x	
	CYP2B6	Enzymatic Activity						x	
	CYP2C8	Enzymatic Activity						x	
	CYP2C9	Enzymatic Activity						x	
	CYP2C19	Enzymatic Activity						x	
	CYP2D6	Enzymatic Activity						x	
	CYP2E1	Enzymatic Activity						x	
	CYP2J2	Enzymatic Activity						x	
	CYP3A4	Enzymatic Activity						x	
	CYP3A5	Enzymatic Activity						x	
	CYP4A11	Enzymatic Activity						x	
CYP4F3B	Enzymatic Activity						x		
CYP19A	Enzymatic Activity						x		
GPCR	Adenosine A2A	Radioligand Filter Binding		x	x	x			
	Adrenergic α1A	Radioligand Filter Binding	x	x		x			
	Adrenergic α2A	Radioligand Filter Binding		x	x	x			
	Adrenergic β1	Radioligand Filter Binding		x	x	x			
	Adrenergic β2	Radioligand Filter Binding	x	x		x			
	Cannabinoid CB1	Radioligand Filter Binding	x	x		x			
	Cannabinoid CB2	Radioligand Filter Binding		x	x	x			
	Cholecystokinin CCK1	Radioligand Filter Binding		x	x	x			
	Cholecystokinin CCK2	Radioligand Filter Binding			x	x			
	Dopamine D1	Radioligand Filter Binding	x	x		x			
	Dopamine D2L	Radioligand Filter Binding		x		x			
	Dopamine D2S	Radioligand Filter Binding			x	x			
	Dopamine D3	Radioligand Filter Binding			x	x			
	Endothelin ETA	FLIPR/Ca Assay			x	x			
	GPBA	Cell Reporter			x	x			
	Histamine H1	Radioligand Filter Binding	x	x		x			
	Histamine H2	Radioligand Binding		x	x	x			
	Mas-related GPCR	FLIPR/Ca Assay			x	x			
	Muscarinic M1	Radioligand Filter Binding		x	x	x			
	Muscarinic M2	Radioligand Filter Binding		x	x	x			
	Muscarinic M3	Radioligand Filter Binding	x	x		x			
	NK3 receptor	Radioligand Filter Binding			x	x			
	Opioid (δ)	Radioligand Filter Binding		x	x	x			
	Opioid (κ)	Radioligand Filter Binding		x	x	x			
	Opioid (μ)	Radioligand Filter Binding	x	x		x			
	Serotonin 5-HT1A	Radioligand Filter Binding			x	x			
	Serotonin 5-HT1B	Radioligand Filter Binding			x	x			
	Serotonin 5-HT2A	Radioligand Filter Binding			x	x			
	Serotonin 5-HT2B	Radioligand Filter Binding	x		x	x			
	Serotonin 5-HT6	Radioligand Filter Binding			x	x			
	Vasopressin V1A	Cell Reporter			x	x			
	Ion Channel	Cav1.2	Patch Clamp	x	x		x		
		GABA(A) α1β2γ2L	FLIPR/Membrane Potential				x		
GABA(A) [Central BDZ]		Radioligand Filter Binding	x	x					
hERG (Kv1.1.1)		Fluorescence Polarization	x	x		x			
Kv7.1		Patch Clamp			x	x			
nAChR α1		FLIPR/Ca assay			x	x			
nAChR α4β2		FLIPR/Ca assay		x					
Nav1.5		Patch Clamp	x	x		x			
NMDA		Radioligand Filter Binding		x	x	x			
Serotonin 5-HT3		Radioligand Filter Binding		x	x	x			
Kinase	ATM	HTRF		x	x	x			
	Aurora A	HotSpot		x	x	x			
	Aurora B	HotSpot		x	x	x			
	c-KIT	HotSpot		x	x	x			
	EGFR	HotSpot		x	x	x			
	FGFR1	HotSpot		x	x	x			
	FMS (VEGFR1)	HotSpot		x	x	x			
	GSK3B	HotSpot		x	x	x			
	IR	HotSpot		x	x	x			
	KDR (VEGFR2)	HotSpot		x	x	x			
	LCK TK	ADP-Glo	x	x		x			
	MKK7	HotSpot			x	x			
	PDK1	HotSpot			x	x			
	PI3Kg (p110g)	ADP-Glo			x	x			
	PTK2	HotSpot			x	x			
	ROCK1	HotSpot			x	x			
	ROCK2	HotSpot			x	x			
	SRC	HotSpot			x	x			
	STK35	HotSpot			x	x			
	TRKA	HotSpot			x	x			

InVEST Panels									
Target Family	Target Name	Assay Format	InVEST18	InVEST44	InVEST59	InVEST77	PDE	CYP	
MAO	MAO-A	Enzymatic Activity		x	x	x			
	MAO-B	Enzymatic Activity		x	x	x			
Nuclear Receptor	Androgen (AR)	Cell Reporter		x	x	x			
	Estrogen- α (ER α)	Fluorescence Polarization			x	x			x
	Glucocorticoid (GR)	Fluorescence Polarization		x	x	x			x
	Progesterone (PR)	Fluorescence Polarization			x	x			x
	Retinoic acid- α (RAR α)	Cell Reporter			x	x			x
Other Enzyme	Acetylcholinesterase	Enzymatic Activity	x	x		x			x
Phosphodiesterase	PDE1A	Enzymatic Activity					x		x
	PDE1B	Enzymatic Activity					x		x
	PDE1C	Enzymatic Activity					x		x
	PDE2A	Enzymatic Activity					x		x
	PDE3A	Enzymatic Activity	x	x		x	x		x
	PDE3B	Enzymatic Activity					x		x
	PDE4A	Enzymatic Activity					x		x
	PDE4B	Enzymatic Activity					x		x
	PDE4C	Enzymatic Activity					x		
	PDE4D	Enzymatic Activity					x		
	PDE4D2	Enzymatic Activity	x	x		x	x		
	PDE5A	Enzymatic Activity					x		
	PDE7A	Enzymatic Activity					x		
	PDE7B	Enzymatic Activity					x		
	PDE8A	Enzymatic Activity					x		
PDE8B	Enzymatic Activity					x			
PDE9A	Enzymatic Activity					x			
PDE10A	Enzymatic Activity					x			
Protease	Cathepsin D	Enzymatic Activity			x	x			
	Paracaspase	Enzymatic Activity			x	x			
Transporter	Dopamine (DAT)	Radioligand Filter Binding	x	x		x			
	GAT1	Radioligand Filter Binding			x	x			
	Norepinephrine (NET)	Radioligand Filter Binding	x	x		x			
	Serotonin (SERT)	Radioligand Filter Binding		x	x	x			

Validated Targets by Family

InVEST target selection is derived from industry consensus publications establishing the molecular targets most frequently associated with clinical adverse drug reactions. The Bowes *et al.* (2012) 44-target panel remains the industry standard for early safety screening. Brennan *et al.* (2024) expanded this foundation with additional kinases, transporters, and emerging targets based on post-market safety data.

Our validated targets span **10 families across 100+ individual targets.**



Scan to learn more



www.reactionbiology.com

1 Great Valley Parkway, Suite 2 Malvern, 19355, PA, USA

+1.610.722.0247

requests@reactionbiology.com

Reaction Biology Corporation

REACTION
BIOLOGY